Chronic Myeloid Leukemia‎ News and Features

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.

More Communication, Support Needed to Manage Symptom Burden in CML

More Communication, Support Needed to Manage Symptom Burden in CML

Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs